MEDIPOST announced on the 26th that it has acquired a Canadian patent by developing the method of culturing high-efficiency mesenchymal stem cells.

The patent entitled ‘Method for culturing mesenchymal stem cells according to the cell size’, which relates to the method associated with the technology of culturing mesenchymal stem cells with high efficiency by controlling the size and culture environment of the cells.

MEDIPOST plans to apply the patented technology to the next-generation stem cell culture platform technology named ‘SMUP-Cell‘ process, for the mass production of the cells with high proliferative and therapeutic capabilities.

MEDIPOST received approval from the Ministry of Food and Drug Safety(MFDS) of Korea for the commencement of Phase 1 clinical trial for the treatment of knee osteoarthritis using an injectable stem cells manufactured using SMUP-Cell technology, in late May.

A company official said, “We have already obtained patents for similar technologies in Korea, Japan, the United States, and Europe,” and further stated that “this patent demonstrates MEDIPOST’s advanced technology in the field of stem cell culture and manufacturing”

The research work led to the patents has been supported by the Ministry of Health and Welfare through the Stem Cells and Regenerative Medicine Consortium Project Grant.